3D bioprinting platform, treatment of colon cancer, ctibitech new technology
2021-11-30 , the Antarctic bear learned that ctibitech, a regenerative medicine company, has developed a new 3D bioprinting platform, which can directly provide more targeted drugs for patients with colorectal cancer.
It is understood that the platform is jointly developed by provdiv Medical University and umhat European hospital in Bulgaria. It can produce a cost-effective and repeatable human colon cancer disease model and can also be used for chemotherapy screening.
Professor csocolin McGuckin, President of ctibitech, said: "the progress of cancer therapy requires new human models to complete drug testing, and our 3D models groundbreaking provide accurate long-term testing strategies to help patients“
Ctibitech's bioprinting Technology
One of the core objectives of ctibitech is to reduce the cost and time of drug development by developing 3D bioprinted human cancer models, which can be used to determine the most effective treatment for individual patients. Over the past seven years, the company has been developing 3D bioprinting technology internally to expand its 3D tissue engineering capability for skin research.
Ctibitech cooperated with the care creations Department of BASF, a chemical company, to study the 3D tissue model of human skin glands. On this basis, ctibitech began to develop a 3D biological printer that can arrange sebaceous glands (skin) micro glands into skin disease models.
In the past, the company has also cooperated with cellink, a Swedish 3D bioprinter supplier, to study new therapies for cancer patients. Using cellink's machine to create tumor tissue models in the laboratory, they are optimistic that this can reduce the expensive loss rate of 40% in preclinical drug screening.
Recently, as part of the novoplasm project alliance, ctibitech became the first company in the world to completely immunize human skin with 3D bioprinting. The company said it was providing hundreds of skin models for research projects to help novoplasm alliance validate its cold plasma wound healing technology for the treatment of infectious burns and skin transplantation.
Developing treatments for colon cancer
Colon cancer is the third leading cause of cancer. More than 1.8 million new patients are diagnosed every year all over the world. The World Health Organization (who) predicts that the number of deaths from colon cancer will reach 12 million in 2030. The late treatment effect of patients with advanced diseases is generally not ideal.
However, according to a recent study conducted by ctibitech, Plovdiv Medical University and umhat European hospital, only 0.1% of drugs can enter clinical application from the laboratory due to the high false positive and false negative rates of preclinical and clinical drug test data.
In order to solve this problem, the partners choose to try to develop a new bioprinting platform to make cost-effective, powerful and repeatable disease models. These models are very similar to cancer cells in vivo, providing more opportunities for individualized treatment.
During the study, these teams produced a 3D bioprinted "adenoid" colon cancer tumor, which showed a similar morphology to the patient's tumor. Therefore, scientists used ctibiotech's ctibiotumour bioprinting technology to reproduce the biomarkers of colorectal cancer, and established a resistance model to standard nursing chemotherapy drugs.
Improve personalized drug development
At present, the development cycle of a new drug takes an average of 15 years and costs nearly 2.6 billion euros to enter the commercialization stage. At the same time, ctibitech said that only 2% of the molecules tested in the preclinical stage of drug development can enter the clinical stage.
According to ctibitech, its technology has the potential to reduce the time for developing new drugs by three years, while the time required for preclinical evaluation can be reduced from six years to two to three years. Ctibio tumour platform can also reduce the cost of drug development chain by about 20%. It is said that each drug developed can save 520 million euros.
The company hopes that its bioprinting platform will better evaluate the safety and effectiveness of candidate drugs, help to implement a personalized medical platform and better predict patients' response to different cancer therapies.
Promoting cancer treatment with 3D printing technology
It is predicted that by 2040, the number of cancer deaths will reach 16 million. Researchers and scientists are also paying more and more attention to how technologies such as 3D bioprinting can help cancer patients' diagnosis and drug development.
Lawrence Livermore National Laboratory (LLNL) has studied how to combine 3D bioprinting with computational flow simulation to better understand how cancer tumors are formed, while Washington State University has developed a 3D printed bone scaffold soaked in soybean, which can resist cancer cells.
Elsewhere, Eshan medical center in Korea has launched 3D printed surgical guidelines to help preserve breast tissue in cancer surgery, while 3D systems and colplant have cooperated to develop 3D bioprinted soft tissue structures suitable for breast reconstruction treatment. Scientists at the California Institute of technology and the University of California, San Francisco also used the 3D printed "chemofilters" to unlock a new cancer targeted treatment method, which can direct chemotherapeutic drugs to affected organs.
In terms of cancer treatment, one of the most important breakthroughs in 3D printing technology is the recent award-winning progress of Tel Aviv University. It is the first glioblastoma printed in 3D using patient cells. Glioblastoma tumor model can improve the treatment of brain cancer, enable clinicians to test the efficacy of new drugs in a real environment, and accelerate drug development.
Antarctic bears also sincerely hope that 3D printing can make more and more breakthroughs in the medical field to help solve more medical problems. I believe this is also the bright future that all mankind is looking forward to!
Original from Nanjixiong.